Journal of the Endocrine Society · 2025
Safety and Effectiveness of Oral Glyburide Suspension in Neonatal Diabetes Mellitus: French Retrospective Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ben Rhaiem Ines, Beltrand Jacques, Vermillac Gaëlle, Kariyawasam Dulanjalee, Geraud Delphine, Besançon Alix, Godot Cécile, Berdugo Marianne, Bonnard Adeline Alice, Cavé Hélène, Nivot-Adamiak Sylvie, Saade Marie Béatrice, Ribault Virginie, Baron Sabine, Petit-Bibal Cécile, Dalla-Vale Fabienne, Bourdet Karine, Morin Carole, Donzeau Aurélie, Gueorguieva Iva, Souchon Pierre-François, Nicolino Marc, Barat Pascal, Coutant Régis, Perge Kevin, Polak Michel
Аннотация
CONTEXT: Neonatal diabetes mellitus (NDM) is a rare condition usually related to an identifiable genetic cause. Sulfonylurea therapy can ensure metabolic control, obviating the need for insulin while also improving neurodevelopmental outcomes. An oral glyburide suspension (OGS; AMGLIDIA) designed for pediatric use was introduced recently to eliminate the drawbacks of using crushed tablets.
OBJECTIVE: To evaluate the long-term effectiveness and safety of the OGS for NDM.
DESIGN: Retrospective cohort study.
SETTING: Fifteen centers in France.
PATIENTS: Consecutive patients started on OGS for NDM in 2015 through 2024.
INTERVENTION: OGS therapy.
MAIN OUTCOME MEASURES: Glycated hemoglobin (HbA1c) values during OGS therapy; growth; and serious adverse events.
RESULTS: Of 27 patients, 22 had KCNJ11 mutations, 4 had ABCC8 mutations, and 1 had a 6q24 anomaly. Median follow-up during OGS therapy was 2.7 years (range, 2 months-9 years). At baseline, median HbA1c was 6.5% (5.8-7.9) overall and 6.5%, 6.4%, and 8.9% in the KCNJ11, ABCC8, and 6q24 subgroups, respectively. The median starting glyburide dose was 0.15 mg/kg/day (range, 0.1-0.185). HbA1c decreased nonsignificantly over time in all subgroups (P = .382), prompting in a small OGS dosage decrease. The last recorded HbA1c value was 6.3%, 5.9%, and 7.4% in the KCNJ11, ABCC8, and 6q24 subgroups, respectively. Serious adverse events were rare, with hypoglycemia in 2 patients during periods of decreased food intake and diarrhea in 1 patient.
CONCLUSION: The OGS was effective in maintaining excellent metabolic control in the long term. The safety profile was good. The OGS should be considered for the first-line treatment of NDM.
OBJECTIVE: To evaluate the long-term effectiveness and safety of the OGS for NDM.
DESIGN: Retrospective cohort study.
SETTING: Fifteen centers in France.
PATIENTS: Consecutive patients started on OGS for NDM in 2015 through 2024.
INTERVENTION: OGS therapy.
MAIN OUTCOME MEASURES: Glycated hemoglobin (HbA1c) values during OGS therapy; growth; and serious adverse events.
RESULTS: Of 27 patients, 22 had KCNJ11 mutations, 4 had ABCC8 mutations, and 1 had a 6q24 anomaly. Median follow-up during OGS therapy was 2.7 years (range, 2 months-9 years). At baseline, median HbA1c was 6.5% (5.8-7.9) overall and 6.5%, 6.4%, and 8.9% in the KCNJ11, ABCC8, and 6q24 subgroups, respectively. The median starting glyburide dose was 0.15 mg/kg/day (range, 0.1-0.185). HbA1c decreased nonsignificantly over time in all subgroups (P = .382), prompting in a small OGS dosage decrease. The last recorded HbA1c value was 6.3%, 5.9%, and 7.4% in the KCNJ11, ABCC8, and 6q24 subgroups, respectively. Serious adverse events were rare, with hypoglycemia in 2 patients during periods of decreased food intake and diarrhea in 1 patient.
CONCLUSION: The OGS was effective in maintaining excellent metabolic control in the long term. The safety profile was good. The OGS should be considered for the first-line treatment of NDM.